Frontiers in Aging Neuroscience · Nov 2, 2026
The Nicotine-Parkinson Paradox and Molecular Hydrogen from the Gut Microbiome
By Kurt Lucas, Katharina L. Lucas, Ulrich Pöschl
The inverse association between tobacco smoking and Parkinson's disease (PD) risk, known as the smoking paradox, is one of the most consistent yet unexplained findings in neuroepidemiology. We propose that it may originate from the gut microbiome, specifically from the modulation of endogenous molecular hydrogen (H₂) production and its downstream signaling along the gut-brain axis, which could explain why transdermal nicotine fails where smoking protects. Despite robust evidence showing 32-60% risk reduction in smokers, clinical trials with nicotine replacement therapy have failed to demonstrate disease-modifying effects. While preclinical studies have identified direct neuroprotective mechanisms of nicotine via nicotinic acetylcholine receptors, Sirtuin 6 (SIRT6) suppression, and anti-inflammatory pathways, these mechanisms alone cannot explain the differences between transdermal nicotine and smoking, including passive exposure. A key distinction is that smoking delivers nicotine and smoke condensates via the oropharyngeal and gastrointestinal route, directly contacting the intestinal mucosa and its resident microbiota, whereas transdermal patches bypass the gut entirely. PD patients consistently exhibit depletion of butyrate-producing and H₂-generating bacteria alongside enrichment of hydrogen sulfide-producing Desulfovibrio species. Smokers, conversely, harbor increased abundance of Prevotella and Bacteroides, taxa equipped with group B [FeFe]-hydrogenases capable of substantial H₂ production. Endogenous H₂ is thought to promote butyrate synthesis, stabilize intestinal barrier function, and reduce systemic inflammation via the gut-brain axis. Molecular hydrogen has anti-inflammatory and mitochondria-protective effects, although the selective antioxidant mechanism originally proposed for it remains debated. We suggest that the application of exogenous molecular hydrogen, deliverable via hydrogen-enriched water, inhalation, or oral formulations designed for colonic release, may offer a novel preventive strategy without tobacco's toxicity. Such a strategy could simultaneously engage direct neuroprotective pathways and microbiome-mediated gut-brain signaling during the critical presymptomatic window of neurodegeneration.